What to Know About This Fund's $15.5 Million Sale of Liquidia as Shares Skyrocket Nearly 260%
2026-05-13 12:43:57 ET
On May 11, 2026, Caprock Group disclosed in a Securities and Exchange Commission filing that it sold 416,686 shares of Liquidia (NASDAQ:LQDA) in the first quarter, an estimated $15.46 million transaction based on quarterly average pricing.
According to a filing with the Securities and Exchange Commission dated May 11, 2026, Caprock Group sold 416,686 shares of Liquidia during the first quarter. The estimated transaction value was $15.46 million, calculated using the period’s average closing price. After the trade, Caprock Group’s position stood at 1,367,235 shares, valued at $51.60 million at quarter-end. The net position change, including price movement, was a decrease of $9.93 million.
Liquidia is a biopharmaceutical company focused on addressing unmet patient needs in pulmonary arterial hypertension through innovative drug formulations and delivery platforms. With a growing portfolio of both proprietary and generic products, the company leverages advanced technology to enhance treatment options for rare cardiopulmonary diseases.
NASDAQ: LQDA
LQDA Trading
21.73% G/L:
$66.17 Last:
2,617,784 Volume:
$55.14 Open:
